prostate cancer

[Cancer Letters] The authors discuss perturbation of cell death in prostate cancer and how new therapeutics could improve treatment outcome in prostate cancer.

[Lab on a Chip] Researchers describe recent advancements in isolation and detection technology and the strength and weaknesses of the three circulating biomarkers.

[Stem Cell Research & Therapy] The authors describe the basic characteristics and biological functions of menstrual blood-derived MSCs-derived small extracellular vesicles.

[Nature Cancer] Scientists reported a Phase I–cleared orally bioavailable MTKI, ESK981, with a novel autophagy inhibitory property that decreased tumor growth in diverse preclinical models of castration-resistant prostate cancer.

[Carrick Therapeutics (Globe Newswire, Inc.)] Carrick Therapeutics announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.

[International Journal of Molecular Sciences] Researchers investigated the functional role and molecular mechanisms of SNHG11 in prostate cancer (PCa) progression. It was revealed that the SNHG11 expression levels were significantly upregulated in PCa tissues, in comparison with those in adjacent normal tissues.